Feasibility of Administering Clonidine as a Pharmacological Challenge in Imaging Studies
Status:
Terminated
Trial end date:
2020-03-17
Target enrollment:
Participant gender:
Summary
This will be a Phase 1, open label study of the pharmacokinetics (PK) and pharmacodynamics
(PD) of clonidine, an alpha-2 adrenergic (a2a) agonist, in healthy volunteers. The primary
aim is to show that the drug regimen is safe and reasonably well tolerated. The secondary aim
is to demonstrate that safety can be monitored with home health devices.